発作性片頭痛の予防治療におけるTEV-48125の2つの投与レジメンとプラセボの有効性および安全性

基本情報

NCT ID: NCT02629861
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 875
治験依頼者名: Teva Branded Pharmaceutical Products R&D, Inc.

概要

The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine

対象疾患

Migraine

介入

Fremanezumab(DRUG)

Placebo(DRUG)

依頼者（Sponsor）

Teva Branded Pharmaceutical Products R&d(INDUSTRY)

実施施設 (25)

Teva Investigational Site 84064

Tokyo, Japan

Teva Investigational Site 84067

Kyoto, Japan

Teva Investigational Site 84062

Osaka, Japan

Teva Investigational Site 84068

Shizuoka, Japan

Teva Investigational Site 84073

Kawasaki, Japan

Teva Investigational Site 84066

Kagoshima, Japan

Teva Investigational Site 84070

Saitama, Japan

Teva Investigational Site 84061

Sendai, Japan

Teva Investigational Site 84072

Chofu-shi, Japan

Teva Investigational Site 84072

Chofu-shi, Japan

Teva Investigational Site 84069

Kai, Japan

Teva Investigational Site 84071

Toyonaka-shi, Japan

Teva Investigational Site 84071

Toyonaka, Japan

Teva Investigational Site 84070

Saitama-shi, Japan

Teva Investigational Site 84064

Chofu-shi, Japan

Teva Investigational Site 84073

Kawasaki-shi, Japan

Teva Investigational Site 84068

Shizuoka, Japan

Teva Investigational Site 84065

Tochigi, Japan

Teva Investigational Site 84067

Kyoto, Japan

Teva Investigational Site 84069

Kaisho, Japan

Teva Investigational Site 84061

Sendai, Japan

Teva Investigational Site 84062

Osaka, Japan

Teva Investigational Site 84065

Shimotsuma, Japan

Teva Investigational Site 84063

Shinjuku-ku, Japan

Teva Investigational Site 84066

Kagoshima, Japan